Neutrophil granulocyte. © Blausen.com staff (2014). "Medical gallery of Blausen Medical 2014". WikiJournal of Medicine 1 (2). DOI:10.15347/wjm/2014.010. ISSN 2002-4436

Infants who show defective immune responses to microbial components are more likely to acquire asthma later in childhood, according to a study of 541 children.

© MaaT Pharma

MaaT Pharma SA has announced €18m Series B financing to boost its microbiome biotherapeutics pipeline.

Ex-Sandoz Head of Global Franchises Rex Clements is taking over as CEO of Centrient Pharmaceuticals. Erstwhile Centrient CEO Karl Rotthier has decided to step down, the company said.

© Valneva SE

French vaccine developer Valneva SA will raise $85m in a financing arrangement with Deerfield and OrbiMed and go Nasdaq to co-fund its Lyme disease programme.

© pixabay/ Jukka Niittymaa

The EMA’s human medicines committee (CHMP) recommended fifteen medicines for approval at its January 2020 meeting.

European venture capital firm Sofinnova Partners announced the promotion of Michael Krel to Partner of the Industrial Biotechnology team. Krel previously served as Principal on the team, where he focused on early-stage deals in Europe and North America.

EuroGuide_2020_Newsletter_800x450.jpg

The 10th edition of the European Biotechnology Science & Industry Guide once more offers an interesting cross-section of the European biotech scene.

Active centre of the IMP dehydrogenase. © University of Luebeck/DESY, Lars Redecke

Researchers at the University of Luebeck have revealed the structure of the IMP dehydrogenase, a central target of T. brucei, which causes sleeping sickness.

Aedes mosquito. © Imperial College London

Scientists at Imperial College London have created a worldwide atlas of dengue virus transmission with much higher spatial resolution than any previous regional- or global-scale estimates.

© Mutabilis SA

The ENABLE project has achieved its initial goals to identify three antibacterial leads, select two antibacterial development candidates and advance one compound into Phase I development.